If you have MS, you already know what the standard drugs do and don't do. They can slow the disease down. They can stretch out the time between relapses. What none of them do is repair damage already done to your myelin — the insulation around your nerves that MS strips away. That gap is the whole reason people start looking at stem cells.
Two things MSCs do that matter here
MSC therapy is studied in MS for two reasons, and it helps to keep them separate.
They calm the immune system
MS is, at its core, your own immune cells attacking myelin as if it were a threat. MSCs behave less like a drug and more like a thermostat — they read an over-inflamed environment and dial it back down, easing off the immune activity driving the damage rather than shutting the whole system off the way broad immunosuppressants do.
They protect the nerves themselves
MSCs release signalling proteins that help neurons survive, and in laboratory work they support the cells responsible for rebuilding myelin. Whether that repair fully translates to people is still an open question. We would rather say that plainly than oversell it.
Where the evidence actually stands
Most of what we know about MSCs in MS comes from laboratory studies and early-phase human trials — the kind designed to establish safety and look for signals, not the large randomised trials that settle a question for good.
What has been encouraging:
Lower markers of inflammation in the nervous system
Some patients reporting fewer relapses
Occasional gains in day-to-day function
What should keep you sceptical:
The trials are small, and follow-up is short
Most lack the placebo controls that would make results airtight
MS fluctuates on its own, which makes any one person's improvement genuinely hard to attribute
If someone tells you MSC therapy is a proven treatment for MS, they are running ahead of the evidence.
What can honestly be said is narrower: the mechanism is plausible, the safety profile in trials so far has been reassuring, and some patients do report meaningful change. That is the truthful version, and it is the one you will hear from us on a call.
How treatment actually runs
For MS, the delivery route matters. Intrathecal administration — into the spinal canal — places cells closer to the central nervous system than an IV infusion does, and for some MS subtypes the physicians will recommend it, sometimes alongside IV. Which route you get is a clinical decision made during your evaluation, not an item you pick off a menu.
Treatment runs across three to five days.
Most patients fly home inside a week.
Follow-up begins thirty days later and continues monthly for a year.
One thing worth being precise about: Regen Cord, our ISO/cGMP-certified laboratory and clinical partner, manufactures the cells, reviews your medical data, and administers the therapy at the clinic. True Regen Medical coordinates everything around that — your evaluation, your records, your travel, your follow-up.
Who we say no to
Not everyone with MS is a candidate, and we do turn people down. What the physicians weigh:
Your MS subtype — relapsing-remitting behaves differently from primary progressive
How far the disease has advanced, and how much function is still there to protect
What you have already tried, and how you responded
Anything in your history that tips the risk side of the ledger too far
If yours is a case where the therapy is unlikely to help you, you will be told that rather than sold to. That happens more often than a clinic's website would lead you to expect.
If you want a real answer about your own case, send your records over. A physician reviews them, and you get a straight assessment either way.